ReviewThe Journal of antimicrobial chemotherapy2018
Tolerability profile of the current antifungal armoury.
Review in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.Clinical pharmacology and therapeutics · 2021Pooled it
- Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants.Antimicrobial agents and chemotherapy · 2024Trial
- Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.Clinical drug investigation · 2023Trial
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Use of Isavuconazole in the Treatment of Cryptococcosis: A Real-World Case Series.Infectious diseases and therapy · 2026Article
- Article
- A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin.International journal of molecular sciences · 2025Review
- Article
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Safety and Tolerability of Antimicrobial Agents in the Older Patient.Drugs & aging · 2023Review
- Design, Synthesis and Antifungal Evaluation of Novel Pyrylium Salt In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2022Article
- Post-Prescription Audit Plus Beta-D-Glucan Assessment Decrease Echinocandin Use in People with Suspected Invasive Candidiasis.Medicina (Kaunas, Lithuania) · 2021Article
- Investigational Agents for the Treatment of Resistant Yeasts and Molds.Current fungal infection reports · 2021Review
- Population differentiation, antifungal susceptibility, and host range of Trichophyton mentagrophytes isolates causing recalcitrant infections in humans and animals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.Medical mycology · 2020Article
- Update on Coccidioidomycosis in the United States and Beyond.Global pediatric health · 2020Review
- Dectin-1 Promotes Type I and III Interferon Expression to Support Optimal Antifungal Immunity in the Lung.Frontiers in cellular and infection microbiology · 2020Article
- Article
- Pre-Existing Liver Disease and Toxicity of Antifungals.Journal of fungi (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The tolerability of available antifungal agents is essential to the final outcome of the management of invasive mycoses. There are limited classes of antifungal agents for use, and they can have serious direct toxicities and/or drug-drug interactions. In this review, we examine the common toxicities noted for antifungal agents and attempt to both identify the issues around the adverse events and provide clinical context for their occurrence in these fragile patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.